Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2020 September;64(3) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2020 September;64(3):234-49

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW  NUCLEAR MEDICINE IN PRECISION ONCOLOGY 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2020 September;64(3):234-49

DOI: 10.23736/S1824-4785.20.03261-6

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Molecular imaging of norepinephrine transporter-expressing tumors: current status and future prospects

Elin PAUWELS 1, 2, Matthias VAN AERDE 1, 2, Guy BORMANS 3, Christophe M. DEROOSE 1, 2

1 Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, University Hospitals Leuven, Leuven, Belgium; 2 Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Belgium; 3 Radiopharmaceutical Research, Department of Pharmacy and Pharmacology, KU Leuven, Leuven, Belgium



The human norepinephrine transporter (hNET) is a transmembrane protein responsible for reuptake of norepinephrine in presynaptic sympathetic nerve terminals and adrenal chromaffin cells. Neural crest tumors, such as neuroblastoma, paraganglioma and pheochromocytoma often show high hNET expression. Molecular imaging of these tumors can be done using radiolabeled norepinephrine analogs that target hNET. Currently, the most commonly used radiopharmaceutical for hNET imaging is meta-[123I]iodobenzylguanidine ([123I]MIBG) and this has been the case since its development several decades ago. The γ-emitter, iodine-123 only allows for planar scintigraphy and single photon emission computed tomography imaging. These modalities typically have a poorer spatial resolution and lower sensitivity than positron emission tomography (PET). Additional practical disadvantages include the fact that a two-day imaging protocol is required and the need for thyroid blockade. Therefore, several PET alternatives for hNET imaging are actively being explored. This review gives an in-depth overview of the current status and recent developments in clinical trials leading to the next generation of clinical PET ligands for imaging of hNET-expressing tumors.


KEY WORDS: Norepinephrine plasma membrane transport proteins; Neural crest tumor; 3-Iodobenzylguanidine; Tomography, emission-computed, single-photon; Positron-emission tomography

top of page